A new study performed by Cannabotech has demonstrated that the company’s range of Integrative-Colon products may be an effective colon cancer treatment, killing 90% of colon cancer cells in a cell model study.
Cannabotech is a biotechnology company pioneering oncological products comprised of cannabis and mushroom extracts. In a recent cell model study, the company has demonstrated that its Integrative-Colon products, which are based on an array of cannabinoids from the cannabis plant and various mushroom extracts, eliminated over 90% of colon cancer cells. The findings offer an exciting prospect for the future of colon cancer treatment.
How did the Integrative Colon products perform?
For their study, the researchers analysed the effectiveness of the Integrative Colon products on a range of colon cancer subtypes, representing different molecular changes that a prevalent in these cancer subtypes. The team compared the composition of the products with the activity of each cannabinoid individually.
The results suggested that the composition of the Integrative Colon products was more effective than each cannabinoid individually, highlighting a strong synergy between the active ingredients. These findings back up claims from Cannabotech that to achieve an effective cannabis colon cancer treatment, it is essential to amalgamate a defined, accurate, and science-based formula that cannot be achieved in any cannabis strain that exists in nature.
Additionally, the study showed the different effects of each cannabinoid on distinct colon cancer subtypes. This echoes the essential need for a individualised approach for patients’ health needs, such as the personalised technology already developed by Cannabotech that will soon hit the market in the UK, US, and Israel at the end of 2022.
The mushroom extracts in the products contain an enriched and high concentration of an active substance called PSK that is extracted from the Trametes mushroom. PSK is known for its anti-cancer properties and has been approved as an oncology treatment in Taiwan, Japan, and South Korea.
The researchers are now looking to assess the effectiveness of the formula in combination with standard chemotherapies. In addition, the team plan to combine the cannabinoid formula with the mushroom Cyathus Striatus as part of the botanical drug development project.
Elhanan Shaked, the CEO of Cannabotech, commented: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment to reduce its side effects. Cannabotech’s solutions will be launched in Israel and the US towards the second half of 2022, while the company’s goal is to define a new standard for the medical cannabis industry.”
Professor Tami Peretz, Senior Oncologist, said: “Colon cancer is one of the most common tumours today, with a significant proportion of patients currently treated with integrative therapies, in combination with traditional methods, including the administration of medical cannabis. Cannabotech’s Integrative products are unique in that they are designed to standards similar to those of the pharmaceutical industry and incorporate many active ingredients. The company’s products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory. Based on these experiments, there is room to perform animal studies and, in the future, to examine the possibility of incorporating these products in colorectal cancer patients.”
Isaac Angel, Cannabotech’s pharmacological consultant, said: “The significant synergistic effect demonstrated by the combination of active ingredients eliminated over 90% of all types of cancer cells used in the study. Furthermore, this was achieved without the presence of THC, which is the cannabinoid substance producing the “high” effect, whereas each of the other cannabinoids tested individually demonstrated different effects on the various cell types. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products and highlight the need for medical care customisation. We shall continue to work to provide a cure for patients.”